evans blue has been researched along with yttrium radioisotopes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Csanda, E | 1 |
| Chen, H; Chen, X; Jacobson, O; Kiesewetter, DO; Liu, Y; Ma, Y; Niu, G; Weiss, ID; Wu, H | 1 |
| Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z | 1 |
3 other study(ies) available for evans blue and yttrium radioisotopes
| Article | Year |
|---|---|
Radiation brain edema.
Topics: Animals; Brain; Brain Edema; Cats; Cimetidine; Dogs; Electrons; Evans Blue; Metiamide; Rabbits; Rats; Yttrium Radioisotopes | 1980 |
Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents.
Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Evans Blue; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Mice; Oligopeptides; Positron-Emission Tomography; Radiochemistry; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes | 2017 |
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2018 |